DEFA14A: ESSA Pharma Adjourns XenoTherapeutics Acquisition Vote

ESSA Pharma Inc. has adjourned its special meeting to approve the XenoTherapeutics acquisition, citing ongoing discussions for revised financial terms.

Summary

• ESSA Pharma Inc. (NASDAQ: EPIX) has adjourned its Special Meeting, originally scheduled for September 10, 2025, to approve the acquisition by XenoTherapeutics, Inc.
• The Special Meeting is now rescheduled for September 29, 2025, at 2:00 p.m. (Pacific Time), and will still be held online.
• The adjournment is to allow for continued discussions regarding possible revised financial terms of the transaction, including the Company's estimated cash forecast and upfront cash available for distribution to shareholders.
• The British Columbia Supreme Court Approval Hearing, previously anticipated for September 12, 2025, has also been postponed, with a new date to be announced.
• Shareholders who have already voted do not need to take any further action at this time.

Sentiment

Score: 3

Explanation: The adjournment of a critical shareholder meeting for an acquisition, specifically to discuss 'revised financial terms' and 'upfront cash available for distribution,' introduces significant uncertainty and suggests potential issues with the original deal structure. This delay and the need for renegotiation are generally negative signals for investors, indicating a higher risk of the transaction falling through or being completed on less favorable terms.

Negatives

• The adjournment of the Special Meeting indicates that the previously agreed-upon financial terms of the acquisition by XenoTherapeutics may not be satisfactory or are subject to revision, introducing uncertainty for shareholders.
• The delay of the British Columbia Supreme Court Approval Hearing further prolongs the transaction timeline and adds to the uncertainty surrounding its completion.
• The need for revised financial terms could potentially lead to a less favorable outcome for ESSA Pharma shareholders regarding the cash distribution.

Risks

• The completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions.
• The potential for the date of the Special Meeting to change again.
• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Disruptions from the Transaction harming ESSA's business, including current plans and operations.
• The ability of ESSA to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• The accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, or outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated.
• Competitive responses to the Transaction.

Future Outlook

The company is actively engaged in discussions to potentially revise the financial terms of the acquisition by XenoTherapeutics, including the cash forecast and upfront cash distribution to shareholders. The Special Meeting has been rescheduled to September 29, 2025, and the court approval hearing will be rescheduled at a later date, indicating the transaction is still under consideration but subject to changes in its terms and timeline.

Management Comments

• The Board of Directors of the Company has approved an adjournment of the special meeting.

Industry Context

This announcement reflects ongoing M&A activity within the biotechnology sector, specifically involving a pharmaceutical company focused on prostate cancer therapies being acquired by a non-profit biotechnology entity. The need for revised financial terms highlights the complexities and potential valuation challenges inherent in such transactions, particularly when involving a non-profit acquirer.

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers is identified as a risk.

Stakeholder Impact

• Shareholders, optionholders, and warrantholders are directly impacted by the delay and potential revision of financial terms for the acquisition, which could affect the value of their holdings or the cash distribution received.
• Employees may face uncertainty regarding the future of the company and their employment as the transaction's terms are renegotiated.

Next Steps

• ESSA Pharma Inc. will hold its Special Meeting on September 29, 2025, at 2:00 p.m. (Pacific Time) via live interactive webcast.
• Discussions regarding possible revised financial terms of the transaction with XenoTherapeutics, Inc. will continue.
• ESSA will issue a further press release to advise of the anticipated date for the rescheduled British Columbia Supreme Court Approval Hearing.

Key Dates

Recommendation

The adjournment of the special meeting and the delay of the court approval hearing, specifically to discuss 'possible revised financial terms' and 'upfront cash available for distribution,' introduce significant uncertainty regarding the previously announced acquisition by XenoTherapeutics. This situation suggests that the original terms may not be satisfactory or that new factors have emerged, potentially leading to a less favorable outcome for shareholders or even the transaction's collapse. Investors should hold to monitor the outcome of these discussions before making further investment decisions, as the risk profile has increased.

Keywords

ESSA Pharma, XenoTherapeutics, Acquisition, Merger, Special Meeting, Adjournment, Financial Terms, Biotechnology, Prostate Cancer, SEC Filing, EPIX